Mercadyne Investments LLC United States

Mercadyne Advisors LLC advises private and public companies regarding capital strategy, business strategy, board governance, and restructuring. 

Mercadyne enables public companies to maximize shareholder value by positioning the company’s capitalization, Board and enterprise such that Wall Street will reward them for their business. 

Mercadyne also provides private companies seeking capital and liquidity an alternative financing path to the conventional, strict venture capital-to-large IPO process. We provide these emerging growth companies with an alternative public offering (APO) or direct public offering (DPO), structure via a public vehicle or small IPO (SIPO) strategy.

Robert Smith
LinkedIn logo Portfolio Manager 

Merck United States

Merck United States

From developing new therapies that treat and prevent disease to helping people in need, we're committed to improving health and well-being around the world.
Dr Luther T. Clark
Global Director, Scientific, Medical and Patient Perspective 

MERCK United States

From developing new therapies that treat and prevent disease to helping people in need, we're committed to improving health and well-being around the world.
Dr Ramesh Kashi
Senior Principal Scientist 

MERCK & Co United States

From developing new therapies that treat and prevent disease to helping people in need, we're committed to improving health and well-being around the world.
Mr Nikos Lioutas
LinkedIn logo Senior Specialist - Digital Innovation & Outreach 

MERCK & Co United States

Mr Jaime Melendez
LinkedIn logo Associate Director, Technology Partnership and Business Development 

Merck & Co. United States

 Led >10 biologics PKPD mathematical modeling and data analysis projects in oncology, diabetes, inflammation and Alzheimer's disease.

- Conceived the idea for a novel technology in the area of antibody drug conjugates to specifically target the tumor cells. Gathered a team of 5 to implement the technology. Got buy-in from senior management. Based on this technology, an antibody drug is being developed in Pfizer (patent in preparation).

- Co-invented a technology to improve the dosing of antibody drugs (patent application filed). A drug based on this technology is in the pipeline.

Specialties: - Feasibility analysis: Assessment of new biotherapeutic drugs, modalities and technologies
- Mechanism based translation: Preclinical to phase 1 clinical trials
- Biotherapeutics PKPD
- Monoclonal antibody drug property and dose selection
- Use of predictive mathematical modeling to design bio-better therapeutics
- Business development: Due diligence for licensing opportunities

Kapil Mayawala
LinkedIn logo Principal Scientist - Quantitative Modeling/Systems Pharmacology 

Merck & Co., Inc. United States

From developing new therapies that treat and prevent disease to helping people in need, we're committed to improving health and well-being around the world.
Dr JoAnne Foody
Global Director for Scientific Affairs, Cardiovascular 

Merck Animal Health United States

Dr Ricardo Mattos
Director of Business Development 

Merck Animal Health United States

Our customers have always known that they can depend on Merck Animal Health for more than just medicines. They count on Merck Animal Health for information, technologies and veterinary services that truly advance animal healthcare. It is our heritage and our mission.

Today, our science supports the precious bond between people and their pets. It also helps protect international public health, ensure food safety and increase protein supplies.

Dr Holger Lehmann
AVP & Global Head, Drug Discovery